PL396633A1 - The use of α-ketoglutarate for the production a drug used in anti-cancer therapy - Google Patents

The use of α-ketoglutarate for the production a drug used in anti-cancer therapy

Info

Publication number
PL396633A1
PL396633A1 PL396633A PL39663311A PL396633A1 PL 396633 A1 PL396633 A1 PL 396633A1 PL 396633 A PL396633 A PL 396633A PL 39663311 A PL39663311 A PL 39663311A PL 396633 A1 PL396633 A1 PL 396633A1
Authority
PL
Poland
Prior art keywords
ketoglutarate
production
cancer therapy
cancer
drug used
Prior art date
Application number
PL396633A
Other languages
Polish (pl)
Other versions
PL217053B1 (en
Inventor
Piotr Niedzielski
Stefan Pierzynowski
Witold Kaczorowski
Katarzyna Mitura
Original Assignee
Politechnika Lódzka
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Lódzka filed Critical Politechnika Lódzka
Priority to PL396633A priority Critical patent/PL217053B1/en
Publication of PL396633A1 publication Critical patent/PL396633A1/en
Publication of PL217053B1 publication Critical patent/PL217053B1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Przedmiotem wynalazku jest zastosowanie ?-ketoglutaranu, w postaci nanoproszku otrzymanego w wyniku modyfikacji ?-ketoglutaranu plazma o czestotliwosci radiowej w atmosferze metanu, do wytwarzania leku hamujacego niekontrolowane namnazanie komórek nowotworowych. Stwierdzono antyproliferacyjne, czyli hamujace rozwój nowotworu na poziomie in vitro, dzialanie ?-ketoglutaranu na poziomie dysregulacji podzialu komórki nowotworowej z fazy G1 mitozy (poczatek podzialu) do fazy S (aktywnej syntezy bialek nowotworowych).The subject of the invention is the use of β-ketoglutarate, in the form of nanopowder obtained as a result of modification of β-ketoglutarate plasma with radio frequency in the methane atmosphere, for the preparation of a drug which inhibits the uncontrolled multiplication of cancer cells. Anti-proliferative, i.e. inhibiting the development of cancer at the in vitro level, activity of β-ketoglutarate at the level of dysregulation of the tumor cell division from the G1 phase of mitosis (the beginning of division) to the S phase (active synthesis of cancer proteins) was found.

PL396633A 2011-10-14 2011-10-14 The use of α-ketoglutarate for the production a drug used in anti-cancer therapy PL217053B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL396633A PL217053B1 (en) 2011-10-14 2011-10-14 The use of α-ketoglutarate for the production a drug used in anti-cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL396633A PL217053B1 (en) 2011-10-14 2011-10-14 The use of α-ketoglutarate for the production a drug used in anti-cancer therapy

Publications (2)

Publication Number Publication Date
PL396633A1 true PL396633A1 (en) 2013-04-15
PL217053B1 PL217053B1 (en) 2014-06-30

Family

ID=48536341

Family Applications (1)

Application Number Title Priority Date Filing Date
PL396633A PL217053B1 (en) 2011-10-14 2011-10-14 The use of α-ketoglutarate for the production a drug used in anti-cancer therapy

Country Status (1)

Country Link
PL (1) PL217053B1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241455B2 (en) 2016-01-15 2022-02-08 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of treating disease by metabolic control of T-cell differentiation

Also Published As

Publication number Publication date
PL217053B1 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
PH12015502839A1 (en) Antiviral compounds
GT201500051A (en) GLUCOSILCERAMIDE SINTASA INHIBITORS
CR20150370A (en) ANTIVIRAL COMPOUNDS
PH12014501561A1 (en) Therapeutically active compounds and their methods of use
CR20200479A (en) Therapeutically active compounds and their methods of use
EA201490707A1 (en) MACRO CYCLIC INHIBITORS FLT3 KINASE
MX345928B (en) Therapeutically active compositions and their methods of use.
EA201490891A1 (en) PYRIDOPYRAZINS, possessing anti-cancer activity through inhibition of FGFR kinase
EA201490636A1 (en) T-CELLS DESIGNED WITH THE HELP OF RNA FOR THE TREATMENT OF MALIGNOUS NON-FORMATIONS
BR112015000399A2 (en) pyrazolyl pyrimidine derivatives
MY162950A (en) Compounds and methods for kinase modulation, and indications therefor
EA201390381A1 (en) TRIAZINOXADIAZOLES
MX350539B (en) Enediyne compounds, conjugates thereof, and uses and methods therefor.
EA201591545A1 (en) C-3 ALKYL AND ALKENYL-MODIFIED BETULINIC ACID DERIVATIVES
MX2015012731A (en) Processes and intermediates for preparing a medicament.
EA201391114A1 (en) METHODS OF USE ALK-INHIBITORS
MX2013010898A (en) Novel pyrimidine derivatives.
NZ704718A (en) Epcam aptamer for detection of cancer stem cells
EP3016715A4 (en) Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy
MY167652A (en) Disposable diaper
IN2014DN06104A (en)
MX2015014344A (en) Cancer therapy.
MX2015007727A (en) 6-chloro-3-(phenyl-d5)-inden-1-one and use thereof.
MX2014001810A (en) Use of ccne2 as a stratification marker in the treatment of breast tumours with novel pan-cdk inhibitors.
MX2013011694A (en) Taxane and abeo-taxane analogs.